drug monitoring

Two experts propose replacing Phase 3 trials with smaller, faster alternatives and post-market surveillance to invigorate the pharmaceutical industry.

Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.

The US regulatory agency recalled 54 percent more drugs from the second to third quarters of 2011.

Forensic labs in the United States should be better equipped to identify a new crop of recreational drug mimics.

Pharmacovigilance must keep pace with global distribution of drugs in resource-limited settings.